Table 4.
Randomized placebo-controlled trials with oral glycoprotein IIb/IIIa inhibitors
| Trial (number of patients) | Agent tested | Indications | Entry criteria | Primary endpoints |
| EXCITE (7232) | Xemilofiban | PCI | Patients with angiographic evidence of | Death, MI, and recurrent revascularization, |
| significant CAD requiring PCI | at 30 and 182 days | |||
| OPUS-TIMI 16 | Orofiban | ACS | Unstable coronary syndromes; Q-wave | Death, MI, and recurrent ischemia, |
| (10,302) | MI, non-Q-wave MI, and UA, in preceding | revascularization, or stroke, at 30 days and | ||
| 72 hours with either ECG changes, | 6 months | |||
| enzyme elevation, or prior CAD | ||||
| SYMPHONY (9233) | Sibrafiban | ACS | ACS event after stabilization | Death, MI, and severe recurrent ischemia, |
| at 90 days | ||||
| SECONDSYMPHONY | Sibrafiban | ACS | ACS event after stabilization | Death, MI, and severe recurrent ischemia, |
| (6671) | at 90 days | |||
| BRAVO (9200) | Lotrafiban | ACS + CVA | Recent MI, UA, TIA or stroke, or PVD | Death, stroke, recurrent ischemia, or |
| revascularization, at 6 months-2 years | ||||
| (stopped prematurely) |
ACS, Acute coronary syndromes; CAD, coronary artery disease; CVA, cerebrovascular accident; ECG, electrocardiogram; MI, myocardial infarction; PCI, percutaneous coronary interventions; PVD, peripheral vascular disease; TIA, transient ischemic attack; UA, unstable angina.